Jazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of patients treated with Erwinaze for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The trial, which was presented at the American Society of Hematology Annual Meeting and Exposition, includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the drug's known safety profile.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Investor's Business Daily (Thu, 11:51AM)
at Zacks.com (Feb 25, 2015)
at Benzinga.com (Feb 24, 2015)
at Investor's Business Daily (Feb 24, 2015)
at Benzinga.com (Feb 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs